Publicaciones en colaboración con investigadores/as de Pfizer (United States) (24)

2024

  1. Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer

    Journal of Clinical Oncology, Vol. 42, Núm. 9, pp. 994-1000

  2. Patient-reported outcomes in high-risk HR+ /HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPEB study

    European Journal of Cancer, Vol. 196

2023

  1. Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients

    Clinical Cancer Research, Vol. 29, Núm. 20, pp. 4166-4177

  2. Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 33, pp. 5118-5130

2022

  1. Mapping genomic loci implicates genes and synaptic biology in schizophrenia

    Nature, Vol. 604, Núm. 7906, pp. 502-508

2021

  1. Genetic identification against traffic in human beings

    WILEY INTERDISCIPLINARY REVIEWS: FORENSIC SCIENCE, Vol. 3, Núm. 1

  2. Predictive and criterion validity of the Cervantes-SF menopause quality of life questionnaire

    Menopause (New York, N.Y.), Vol. 28, Núm. 8, pp. 935-942

  3. Urinary Microbiome: Yin and Yang of the Urinary Tract

    Frontiers in Cellular and Infection Microbiology, Vol. 11

2017

  1. Cardiovascular efficacy and safety of bococizumab in high-risk patients

    New England Journal of Medicine, Vol. 376, Núm. 16, pp. 1527-1539

2016

  1. La evaluacion de factores de riesgo y el asesoramiento durante 12 meses reduce el riesgo metabolico y cardiovascular en pacientes con trastornos del espectro esquizofrenico con sobrepeso u obesidad: Estudio CRESSOB

    Actas Espanolas de Psiquiatria, Vol. 44, Núm. 1, pp. 20-29

2014

  1. Erratum to: Effectiveness of pregabalin as monotherapy or combination therapy for neuropathic pain in patients unresponsive to previous treatments in a Spanish primary care setting (Clinical Drug Investigation (2013) 33, (633-645) DOI: 10.1007/s40261-013-0116-7)

    Clinical Drug Investigation

  2. Fe de errores de «Prevalencia del dolor neuropático (DN), según DN4, en atención primaria»

    Semergen

  3. Prevalence of Metabolic Syndrome in Spanish patients with schizophrenia and overweight. The CRESSOB study

    Actas Espanolas de Psiquiatria, Vol. 42, Núm. 1, pp. 9-17

2013

  1. Effectiveness of pregabalin as monotherapy or combination therapy for neuropathic pain in patients unresponsive to previous treatments in a Spanish primary care setting

    Clinical Drug Investigation, Vol. 33, Núm. 9, pp. 633-645

2009

  1. Lipoatrophy in GH deficient patients treated with a long-acting pegylated GH

    European Journal of Endocrinology, Vol. 161, Núm. 4, pp. 533-540

2008

  1. Linguistic adaptation into Spanish and psychometric validation of the ID-Pain© questionnaire for the screening of neuropathic pain

    Medicina Clinica, Vol. 131, Núm. 15, pp. 572-578

2007

  1. Authors' Response

    Journal of Pain and Symptom Management

  2. Cross-sectional evaluation of patient functioning and health-related quality of life in patients with neuropathic pain under standard care conditions

    European Journal of Pain, Vol. 11, Núm. 3, pp. 244-255

  3. Validity and reliability of the Spanish version of the DN4 (Douleur Neuropathique 4 questions) questionnaire for differential diagnosis of pain syndromes associated to a neuropathic or somatic component

    Health and Quality of Life Outcomes, Vol. 5

2006

  1. Adaptación lingüística y validación al castellano de la escala LANSS (Leeds Assessment of Neuropathic Symptoms and Signs) para el diagnóstico diferencial del dolor neuropático

    Medicina Clinica, Vol. 127, Núm. 13, pp. 485-491